<img src="https://ml.globenewswire.com/Resource/Download/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Cosmos.png" alt="Cosmos Health Inc."/>CHICAGO, June 17, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=BLEIdprAKjUZAe1_Ls-DlIPjy6nppbFOl1yBvESsreSPFvKy-yO0Aw-zZcHb7Lz8fa9XNilYrpDSPp4bwAtUtq54Po9jiRnC-80J7N1t_VA=" rel="nofollow" target="_blank" title="">Cosmos Health Inc.</a> ("Cosmos Health" or the “Company”)<a href="https://www.globenewswire.com/Tracker?data=Sz1sSafK1j2DczJsCGS6BeFKPhVEy9mzN4LkUNJ0i-2Q3BJFKkwBqb6stemweOLJSEQ9-OsNB3QA4KroYccReRHjgnSptpZnN8idErxXam8=" rel="nofollow" target="_blank" title=""> (NASDAQ:COSM)</a>, a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") to produce three pharmaceutical products. Under the agreement, Cana will manufacture the following products for Pharmex at its EU-GMP-licensed, EMA-certified facility, with combined volumes of approximately 2.86 million units over the five-year term. <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:22%; width:22%; min-width:22%;;vertical-align: middle; text-align: left; padding-left: 10.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Product</td><td style="max-width:22%; width:22%; min-width:22%;;vertical-align: middle; text-align: left; padding-left: 10.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Active Ingredient</td><td style="max-width:22%; width:22%; min-width:22%;;vertical-align: middle; text-align: left; padding-left: 10.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Pharmaceutical Form</td><td style="max-width:17%; width:17%; min-width:17%;;vertical-align: middle; text-align: left; padding-left: 10.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Annual Units</td><td style="max-width:17%; width:17%; min-width:17%;;vertical-align: middle; text-align: left; padding-left: 10.0px; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Five-Year Total</td></tr><tr><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">BETAFUSIN®</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Betamethasone, Fusidic Acid</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Cream</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">450,000</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">2,250,000</td></tr><tr><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">BOTAFEX®</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Minoxidil</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Cutaneous Solution</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">65,000</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">325,000</td></tr><tr><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">BUDESODERM®</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Budesonide</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Cream / Cutaneous Solution</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">57,000</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">285,000</td></tr><tr><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">Total</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; "> </td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; "> </td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">572,000</td><td style="vertical-align: middle; text-align: left; padding-left: 10.0px; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: top ; ">2,860,000</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td></tr></table> The agreement reinforces Cosmos Health's role as a contract manufacturer of pharmaceutical products and supports higher utilization of its EU manufacturing capacity. By leveraging Cana's licensed production capabilities, the Company aims to deepen its long-term manufacturing partnerships and strengthen recurring revenue from its higher-margin contract manufacturing activities. Founded in 1981, Pharmex is a Greek pharmaceutical company with over 40 years in medicinal products and dermocosmetics. It develops and produces its own products and serves as the exclusive local distributor for international partners. Pharmex products are available in more than 20 countries across Europe, the Middle East, Asia, Africa and Latin America. Greg Siokas, CEO of Cosmos Health, stated: "This five-year agreement with Pharmex reflects the strength of our manufacturing platform and the trust that pharmaceutical partners place in Cana Laboratories. Contract manufacturing is an important pillar of our vertically integrated model, allowing us to maximize the value of our EU-licensed facilities while building stable, long-term relationships. We look forward to delivering for Pharmex and to expanding these partnerships over time.” About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a href="https://www.globenewswire.com/Tracker?data=9KZtsGT6fB1lzH0dwErd5EEDXmnr-7VSCDOUFWczqycPJyf4mgLuVbtaCg0X5qgkR0hVQ7zKzMONvqPh_w-HNs1Qr040qAhvvurd7yHtTB_qLEl7lmlHMzatEeM3hXxi" rel="nofollow" target="_blank" title="">www.cosmoshealthinc.com</a>, <a href="https://www.globenewswire.com/Tracker?data=I4SpqcXAv6llypyYz4lauKdL9r9IsN-lxxnCn16lg6Ivp0jULUbRu8UvxvWEKvicymflBn3KVvrkuqn9J4EJNowVDgHdnfAHjBHn8EKyHoU=" rel="nofollow" target="_blank" title="">www.skypremiumlife.com</a>, <a href="https://www.globenewswire.com/Tracker?data=9KZtsGT6fB1lzH0dwErd5D4IUqWYWmvUzyqsR69i19sNK62ykW8TmUNiOgpfUlawqDn_9HxiCieJAzvjE2kFhg==" rel="nofollow" target="_blank" title="">www.cana.gr</a>, <a href="https://www.globenewswire.com/Tracker?data=WRmd3RRtbbGbytOannDczomMzsA1LSJb5mFwUlzdbimBTcZsaxzv7XFi06Zh1lYqUjl8-01WW8auuFLi7VYgU7IzatZ3ab3WakN_qOWX79M=" rel="nofollow" target="_blank" title="">www.zipdoctor.co</a>, <a href="https://www.globenewswire.com/Tracker?data=9KZtsGT6fB1lzH0dwErd5JW-1qk8QUVLW_iK9QVpKI3ejM3yLddppY1aUImD_iov44sZ50IDEcjKF0u7ePHEUGUj1A1kWm835OxYd6_KYeM=" rel="nofollow" target="_blank" title="">www.cloudscreen.gr</a>, as well as <a href="https://www.globenewswire.com/Tracker?data=VL5X8GVmm0FD5omDQ82UyMS9sQXYz0LqbpUJB46wLprN27TwKQUOI3bduukwiKzJjrSp-o6BM9cAXMrKbhhlIb4gNk9nP9FLU7PqGhiK-V6BW_I_v0FsJtUwi96_MHYo" rel="nofollow" target="_blank" title="">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=cMj4dTcNMAOQZeA_gTk1dYXrnW_GtBlAIbwCupYSVOqgopPdN4HZ2ccgIs15HETREo34IOwPjYprpKbKXNSltOuGv60WcaQmpLp0yGQuvx0=" rel="nofollow" target="_blank" title="">X</a>. Forward-Looking Statements With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (<a href="https://www.globenewswire.com/Tracker?data=I4SpqcXAv6llypyYz4lauDLKLQCPp_dRWBdt6MSb7tDXh5J-lX6eCyG7mmDm9gunPlkA-cIXzZvtGUdcy1x7hQ==" rel="nofollow" target="_blank" title="">www.sec.gov</a>). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements. Investor Relations Contact: BDG Communications <a href="https://www.globenewswire.com/Tracker?data=F3ht9k_dRd6HvfU_5fh0Kf8kX6XxefhaMUoGNlRz1YLYXYGrcLj599FCi4vh77tUFudLoRKIwWh95ZF5IsmXQxVbeIgio2LOe78xLvqBeE9v23D_6EU-eeU3BfVD0Kbb" rel="nofollow" target="_blank" title="cosm@bdgcommunications.com">cosm@bdgcommunications.com</a> <img alt="" src='https://ml.globenewswire.com/media/MDE4Njk5ZmUtMTlhNy00MDY1LTk4OGItYjU3ZGIyOGM2MmViLTEzMDk2NDQtMjAyNi0wNi0xNy1lbg==/tiny/Cosmos-Health-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn